Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics (OA), have the potential to increase medication adherence in adult patients with schizophrenia. This increas...
Introduction: Schizophrenia (SCZ) is a severe mental disorder imposing substantial healthcare burden to society. Data quantifying the non-healthcare societal burden of SCZ is limited, esp...
Long-acting injectable (LAI) antipsychotics are recommended by clinical guidelines for patients with schizophrenia who struggle with adherence and/or recurrent relapses. However, LAI util...
Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...
Background
Schizophrenia (SCZ) is most likely to develop in young adulthood. Using data from a single state, we describe the demographic and clinical characteristics of young adults in t...
Background: Limited evidence is available regarding the economic burden associated with treatment-resistant depression (TRD) among US Veterans.
Objective: To compare the economic burden o...
Background
Schizophrenia (SCZ) likely leads to changes in and/or loss of employment, which can result in changes to insurance coverage or “churn”. Since patients with schizophrenia are ty...
Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...